ADB COMBINATION FOR USE IN HCV TREATMENT

摘要

Combination of ADF for use in the treatment of HCV. # The present invention presents combinations of antiviral agents for use in therapies without interferon and ribavirin in the treatment of HCV. Preferably, the treatment is for a short treatment time, such as no more than 12 weeks. In one aspect, the use of combinations of antiviral agents in therapies comprises administering at least two direct-acting antiviral agents without interferon and neither ribavirin to a subject with HCV infection.